Pernix Therapeutics Holdings, Inc., a distinction biologic company fundamentally focused on the pediatric market, today announced the acquisition of 100% of the outstanding fellowship interest in Macoven Pharmaceuticals, L.L.C. for approximately $2.2 million (which includes inventory of approximately $1.2 million), its entry into a $10 million credit facility with Regions Bank and the repurchase of 2,000,000 shares of its common stock from one of its employees in a privately negotiated transaction.

More: - Read the rest here